RNAi in arthritis: Prospects of a future antisense therapy in inflammation

Maroun Khoury; Christian Jorgensen; Florence Apparailly

RNAi in arthritis: Prospects of a future antisense therapy in inflammation

Maroun Khoury, Christian Jorgensen, Florence Apparailly

Research output: Contribution to journal › Scientific review › peer-review

12 Scopus citations

Abstract

Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.

Original language	American English
Pages (from-to)	483-489
Number of pages	7
Journal	Current Opinion in Molecular Therapeutics
Volume	9
Issue number	5
State	Published - 22 Oct 2007
Externally published	Yes

Keywords

Biotherapy
Inflammation
Rheumatoid arthritis
RNA interference
TNFα

Fingerprint Dive into the research topics of 'RNAi in arthritis: Prospects of a future antisense therapy in inflammation'. Together they form a unique fingerprint.

Cite this

@article{08b8760f6da14cdba7c68fb8d5f8f19a,

title = "RNAi in arthritis: Prospects of a future antisense therapy in inflammation",

abstract = "Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.",

keywords = "Biotherapy, Inflammation, Rheumatoid arthritis, RNA interference, TNFα, Biotherapy, Inflammation, Rheumatoid arthritis, RNA interference, TNFα",

author = "Maroun Khoury and Christian Jorgensen and Florence Apparailly",

year = "2007",

month = oct,

day = "22",

language = "American English",

volume = "9",

pages = "483--489",

journal = "Current Opinion in Molecular Therapeutics",

issn = "1464-8431",

publisher = "Current Drugs Ltd.",

number = "5",

}

TY - JOUR

T1 - RNAi in arthritis: Prospects of a future antisense therapy in inflammation

AU - Khoury, Maroun

AU - Jorgensen, Christian

AU - Apparailly, Florence

PY - 2007/10/22

Y1 - 2007/10/22

N2 - Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.

AB - Rheumatoid arthritis is a chronic autoimmune disease of unknown etiology that is characterized by chronic systemic inflammation, mainly affecting the joints, leading to subsequent destruction of the cartilage and bone. RNA interference (RNAi) has been used as a remarkable new research tool to control gene expression and is ultimately envisioned to be useful in clinical treatments. The potential application of RNAi-based therapy in rheumatoid disorders is evaluated. The first successful attempts at TNFalpha silencing by local and systemic delivery of small interfering RNA in experimental arthritic models are discussed. In addition, RNAi and current biotherapies used in the clinic are compared and contrasted.

KW - Biotherapy

KW - Inflammation

KW - Rheumatoid arthritis

KW - RNA interference

KW - TNFα

KW - Biotherapy

KW - Inflammation

KW - Rheumatoid arthritis

KW - RNA interference

KW - TNFα

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35348895807&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=35348895807&origin=inward

M3 - Scientific review

VL - 9

SP - 483

EP - 489

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 5

ER -